A Retrospective, cohort study to evaluate the treatment outcomes of nab-Paclitaxel/gemcitabine versus gemcitabine mono-therapy and FOLFIRINOX in patients with metastatic pancreatic adenocarcinoma

Trial Profile

A Retrospective, cohort study to evaluate the treatment outcomes of nab-Paclitaxel/gemcitabine versus gemcitabine mono-therapy and FOLFIRINOX in patients with metastatic pancreatic adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results assessing treatment outcomes in nab-Paclitaxel/gemcitabine versus FOLFIRINOX (n=414), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top